An observational study in Pertussis (Whooping Cough), sponsored by Sanofi. Active, not recruiting at 1 site in France. Open to female participants aged 15 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Sanofi · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Whooping Cough by Sanofi — 1 open to participants now, 2 under way, 1 of them phase 3. Whooping Cough · Sanofi.
Among the 83 studies in Whooping Cough by Sanofi, this one has the largest planned enrollment of the 11 observational ones that give a count, is the only one that started in 2024, is one of 11 observational ones, and was the 82nd registered.
291 studies on the registry are indexed under Whooping Cough; 24 are open to participants now.
Browse Whooping Cough studies →1 of the 83 studies in Whooping Cough by Sanofi is open now. Recruiting first, the newest first:
Sanofi
Ages 30 days–45 days · Healthy volunteers
Of the 14 Whooping Cough studies recruiting now, 2 (14%) set no upper age limit and 11 (79%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 15 Years to 49 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 45 · Phase 4 18
First in 1999; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 365,000 is above the median of 510 across 60 observational studies indexed under Whooping Cough.
Median enrollment 594 across the 72 interventional studies, 3,214 across the 11 observational. Of the 81 that completed or were terminated, 46 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
1 of the studies in Whooping Cough by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06258057SanofiSafety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During Pregnancy | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 83 studies in Whooping Cough by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety of Adacel vaccine among pregnant individuals exposed to Adacel at any point between the 1st day of the 27th week of gestation up to the end of pregnancy and their offspring (ie, Adacel-exposed cohort), in comparison with pregnant individuals not vaccinated with any Tdap vaccines during pregnancy and their offspring (ie, Tdap-unvaccinated comparator cohort).
The primary objectives are to estimate incidence rates and relative risks for each prespecified pregnancy outcome in Adacel-exposed and Tdap-unvaccinated comparator cohorts and for each prespecified adverse birth outcome in the offspring of both cohorts.
The secondary objectives are to estimate incidence rates and relative risks for each prespecified adverse fetal and neonatal outcome in the offspring of Adacel-exposed and Tdap unvaccinated comparator cohorts and for each prespecified adverse outcome for pregnant individuals in both cohorts.
This is a retrospective cohort study utilizing existing EHR data to identify eligible pregnant individuals, with an observation period spanning January 2016 through December 2024. Given this study design, follow-up for all pregnancies with documented deliveries is expected to be complete by December 2025.
The study report is expected to be completed by 31 December 2026.
The study population will be comprised of 2 cohorts of pregnant individuals with pregnancy onset from 01 January 2016 through 31 December 2024. Infants born from this study population of pregnant individuals with singleton gestation pregnancies will be eligible for inclusion in this study. Eligible live born infants must be born on 01 October 2025 or prior to this date, to allow adequate follow-up time
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For pregnant individuals:
For offspring:
Exclusion Criteria:
For pregnant individuals:
For offspring:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort will include all pregnant individuals with a record of Adacel vaccination during the third trimester of pregnancy (ie, first day of 27th week of gestation up to the end of pregnancy) and their offspring
Other: Not applicable / database analysis
Cohort will include all pregnant individuals meeting eligibility criteria and with no record of any Tdap vaccination from pregnancy onset date until the end of pregnancy and their offspring
Other: Not applicable / database analysis
Not applicable / database analysis
Pregnancy outcome: Live birth
Incidence rates of live births in Adacel-exposed and Tdap-unvaccinated comparator cohorts
Time frame: From 1st day of the 27th week of gestation up to 42 weeks gestation
Pregnancy outcome: Still birth/fetal demise
Incidence rates of still birth/fetal demise in Adacel-exposed and Tdap-unvaccinated comparator cohorts
Time frame: From 1st day of the 27th week of gestation up to 42 weeks gestation
Pregnancy outcome: Therapeutic abortion
Incidence rates of therapeutic abortion in Adacel-exposed and Tdap-unvaccinated comparator cohorts
Time frame: From 1st day of the 27th week of gestation up to 42 weeks gestation
Birth outcome: Preterm birth
Incidence rates of preterm birth in live born infants of both Adacel-exposed and Tdap-unvaccinated comparator cohorts
Time frame: From 1st day of the 27th week of gestation and less than 37 weeks gestation
Birth outcome: Low birth weight
Incidence rates of low birth weight in live born infants of both Adacel-exposed and Tdap-unvaccinated comparator cohorts
Time frame: From 1st day of the 27th week of gestation up to 42 weeks gestation
Birth outcome: Small for gestational age
Incidence rates of small for gestational age in live born infants of both Adacel-exposed and Tdap-unvaccinated comparator cohorts
Time frame: From 1st day of the 27th week of gestation up to 42 weeks gestation
Adverse neonatal outcome: Neonatal death
Incidence rates of neonatal death in the offspring of Adacel-exposed and Tdap-unvaccinated comparator cohorts
Time frame: From birth up to 28 days post-birth
Adverse neonatal outcome: Neonatal sepsis
Incidence rates of neonatal sepsis in the offspring of Adacel-exposed and Tdap-unvaccinated comparator cohorts
Time frame: From birth up to 28 days post-birth
Adverse neonatal outcome: Neonatal respiratory distress
Incidence rates of neonatal respiratory distress in the offspring of Adacel-exposed and Tdap-unvaccinated comparator cohorts
Time frame: From birth up to 28 days post-birth
Adverse neonatal outcome: Congenital anomalies
Incidence rates of congenital anomalies (major and minor) in the offspring of Adacel-exposed and Tdap-unvaccinated comparator cohorts
Time frame: From birth up to 28 days post-birth
Adverse neonatal outcome: Neonatal/early infancy intensive care admissions for bronchopulmonary dysplasia
Incidence rates of neonatal/early infancy intensive care admissions for bronchopulmonary dysplasia in the offspring of Adacel-exposed and Tdap-unvaccinated comparator cohorts
Time frame: From birth up to 28 days post-birth
Adverse fetal outcome: Fetal growth arrest (restriction)
Incidence rates of fetal growth arrest (restriction) in Adacel-exposed and Tdap-unvaccinated comparator cohorts
Time frame: From 1st day of the 27th week of gestation up to 42 weeks gestation
Adverse outcomes in pregnant individuals: Preterm labor
Incidence rates of Preterm labor in Adacel-exposed and Tdap-unvaccinated comparator cohorts
Time frame: From 1st day of the 27th week of gestation and less than 37 weeks gestation
Adverse outcomes in pregnant individuals: Preeclampsia/eclampsia
Incidence rates of preeclampsia/eclampsia in Adacel-exposed and Tdap-unvaccinated comparator cohorts
Time frame: From 1st day of the 27th week of gestation up to 42 days postpartum
Adverse outcomes in pregnant individuals: Postpartum hemorrhage
Incidence rates of postpartum hemorrhage in Adacel-exposed and Tdap-unvaccinated comparator cohorts
Time frame: Within 24 hours of delivery up to 28 days postpartum
Adverse outcomes in pregnant individuals: Placental abruption
Incidence rates of placental abruption in Adacel-exposed and Tdap-unvaccinated comparator cohorts
Time frame: From 1st day of the 27th week of gestation up to 42 weeks gestation
Adverse outcomes in pregnant individuals: Premature rupture of membranes
Incidence rates of premature rupture of membranes in Adacel-exposed and Tdap-unvaccinated comparator cohorts
Time frame: From 1st day of the 27th week of gestation up to 42 weeks gestation
Adverse outcomes in pregnant individuals: Chorioamnionitis
Incidence rates of chorioamnionitis in Adacel-exposed and Tdap-unvaccinated comparator cohorts
Time frame: From 1st day of the 27th week of gestation up to 42 weeks gestation
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.
Of 22 observational studies under Whooping Cough, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 35 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.